Identification of the best cut-off points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis
© Kostik et al; licensee BioMed Central Ltd. 2014
Published: 17 September 2014
Macrophage activation syndrome (MAS) – is a severe life-threatening hematological condition, mostly complicated systemic juvenile idiopathic arthritis (SJIA). Early detection of MAS can lead to appropriate therapeutic interventions and change the outcomes. There are no strict criteria for early MAS detection in SJIA. Currently applied HLH criteria can determinate only advanced stage of MAS, which lead to delay diagnosis, late start of specific treatment and associated with poor outcomes. There are several sets of preliminary criteria of MAS in SJIA.
The purpose of our study was to detect early clinical and laboratorial signs able to discriminate macrophage activation syndrome (MAS) from active systemic juvenile idiopathic arthritis (SJIA) without MAS.
Our retrospective study was based on reviewing the medical charts of the children, admitted to the rheumatology department with active SJIA and definite MAS (n=18) and without MAS (n=40). We evaluated the data related to SJIA and MAS at the moment of the patient’s admission. If the patient had signs of MAS since admission or developed definite MAS later during this flare he was referred to the main group. The children, who did not have MAS during the flare episode and did not have MAS in the past medical history, were in the control group. We calculated the cut-off points for MAS parameters, performed the analysis of sensitivity and specificity, identified the predictors and provided the preliminary diagnostic rule through “the number of criteria present” approach.
The clinical signs were relevant to MAS in SJIA: oligoarthicular disease course (OR=5.6), splenomegaly (OR=67.6), hemorrages (OR=33.0), respiratory failure (OR=11.3). The involvement of wrist (OR=0.2), MCP (OR=0.1) and PIP joints (OR=0.1) were protective against MAS development. The best cut-offs for laboratorial parameters were PLT≤211*109/l, WBC≤9.9*109/l, AST>59.7 U/l, LDH>882 U/l, albumin≤2.9 g/dl, ferritin>400 μg/l, fibrinogen≤1.8 g/l, proteinuria. The laboratorial variables were more precise in the discrimination of early MAS than clinical: any 3 or more laboratorial criteria provided the highest specificity (1.0) and sensitivity (1.0) and OR – 2997.
We detected clinical and laboratorial markers and created preliminary diagnostic (laboratorial) guidelines for early discrimination of MAS in active SJIA.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.